Construct validity and minimal important diff erence of 6-minute walk distance in survivors of acute respiratory failure

KS Chan; ER Pfoh; L Denehy; D Elliott; AE Holland; VD Dinglas; DM Needham

Journal article

Construct validity and minimal important diff erence of 6-minute walk distance in survivors of acute respiratory failure

KS Chan, ER Pfoh, L Denehy, D Elliott, AE Holland, VD Dinglas, DM Needham

Chest | ELSEVIER | Published : 2015

DOI: 10.1378/chest.14-1808

Abstract

OBJECTIVE: Th e 6-min walk distance (6MWD), a widely used test of functional capacity, has limited evidence of construct validity among patients surviving acute respiratory failure (ARF) and ARDS. The objective of this study was to examine construct validity and responsiveness and estimate minimal important diff erence (MID) for the 6MWD in patients surviving ARF/ARDS . METHODS: For this secondary data analysis of four international studies of adult patients surviving ARF/ARDS (N 5 641), convergent and discriminant validity, known group validity, predictive validity, and responsiveness were assessed. MID was examined using anchor- and distribution-based approaches. Analyses were performed wi..

View full abstract

University of Melbourne Researchers

Linda Denehy Author

Related Projects (1)

Evaluation of an exercise rehabilitation program for patients who survive a stay in the intensive care unit

Intensive care medicine has improved survival in critically ill patients. However, international literature reports poor quality of life and..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

This research was supported by the National Heart, Lung, and Blood Institute [R24HL111895, R01HL091760, R01HL091760-02S1, R01HL096504, and P050HL7399], the Johns Hopkins Institute for Clinical and Translational Research [UL1TR000424-06], the Albuterol to Treat Acute Lung Injury (ALTA), the Early vs Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (EDEN), and the Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (OMEGA) trials [contracts for sites participating in this study: HSN268200536170C, HHSN268200536171C, HHSN268200536173C, HHSN268200536174C, HSN268200536175C, and HHSN268200536179C]. The Elliott trial was supported by the Australian National Health and Medical Research Council (NHMRC) [Grant 352407]. The Denehy trial was completed with funds from the NHMRC [Grant 454717], the Physiotherapy Research Foundation, the Austin Hospital Medical Research Foundation, and the Australian and New Zealand Intensive Care Society.